• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Endoxan
    / Megapharm


    Active Ingredient
    Cyclophosphamide 500 mg, 1 g

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 X 1 g

    partial basket chart 26706 5166

    Vial

    1 X 500 mg

    partial basket chart 26705 5165

    Related information


    Dosage

    See prescribing information for full details.


    Indications

    Malignant lymphoma, Hodgkin disease, lymphocytic lymphoma, mixed cell type lymphoma, Burkitt lymphoma, multiple myeloma, leukememia, mycosis fungoides, neuroblastoma, ovary adenocarcinoma, retinoblastoma, breast carcinoma, SLE.


    Contra-Indications

    Hypersensitivity, patients with severely depressed bone marrow function, pregnancy, lactation.


    Special Precautions

    Use in pregnancy and lactation, patients with leukopenia, thrombocytopenia, tumor cell infiltration of bone marrow, previous radiation therapy, previous cytotoxic therapy, impaired hepatic function, impaired renal function, interruption or modification of dosage should be considered for patients who develop bacterial, fungal or viral infections. This is especially true for patients receiving concomitant steroid therapy or who have recently received steroid therapy, since such infections may be fatal. May suppress positive reactions to the following skin tests: Candida, mumps, Trichophyton and tuberculin purified protein derivative (PPD). Serum pseudocholinesterase may be decreased. Blood and urine uric acid levels may be increased. May produce a false-positive Papanicolaou test.


    Side Effects

    Secondary neoplasia has developed with cyclophosphamide alone or with other antineoplastic drugs or radiation therapy. Leukopenia is an expected effect and is used as a guide to dosage. Thrombocytopenia or anemia occur rarely. Anorexia, nausea, vomiting, diarrhea and stomatitis are common. Urinary tract complications occur in about 25% of cases and acute hemorrhagic cystitis occurs in 7-12%. (SIADH) has been reported with i.v. doses greater than 50 mg/kg body weight. Alopecia, interstitial pulmonary fibrosis, cardiotoxicity, hypersensitivity reactions (type 1).


    Drug interactions

    Allopurinol, ACE inhibitors, doxorubicin, oral hypoglycemics, liver enzyme inducers e.g. rifampicin.


    Manufacturer
    Baxter Oncology, Germany
    Licence holder
    CLOSE